Gerd Auffarth

CIK: 0001649867

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

OTLK

Outlook Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

OTLK
Outlook Therapeutics, Inc.
Oct 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
58.6K shares-
OTLK
Outlook Therapeutics, Inc.
Oct 1, 2025
Award(A)
Stock Option (Right to Buy)
Direct
286.7K shares-
OTLK
Outlook Therapeutics, Inc.
Oct 3, 2024
Award(A)
Stock Option (Right to Buy)
Direct
12.1K shares-
OTLK
Outlook Therapeutics, Inc.
Oct 1, 2024
Award(A)
Stock Option (Right to Buy)
Direct
56.6K shares-
OTLK
Outlook Therapeutics, Inc.
Oct 1, 2024
Award(A)
Stock Option (Right to Buy)
Direct
29.5K shares-

		Type	Shares	Price		Ownership
Oct 3, 2025	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	58,648	-	-	Direct
Oct 1, 2025	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	286,734	-	-	Direct
Oct 3, 2024	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	12,082	-	-	Direct
Oct 1, 2024	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	56,636	-	-	Direct
Oct 1, 2024	OTLK Outlook Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	29,493	-	-	Direct

1-5 of 5 transactions

About Auffarth Gerd

Auffarth Gerd (SEC CIK 0001649867) files insider reports with the SEC as Director of Outlook Therapeutics, Inc. (OTLK).

Signal8 holds 2 ownership filings by Auffarth Gerd, all Form 4s, filed between Oct 3, 2024 and Oct 3, 2025. Those filings report 5 transactions, from Oct 1, 2024 to Oct 3, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Auffarth Gerd's filings is in ISELIN, NJ.

Recent filings by Auffarth Gerd

Oct 3, 2025: Grant or award of OTLK derivative securities (Form 4, code A).
Oct 1, 2025: Grant or award of OTLK derivative securities (Form 4, code A).
Oct 3, 2024: Grant or award of OTLK derivative securities (Form 4, code A).
Oct 1, 2024: Grants or awards of OTLK derivative securities (2 lines, Form 4, code A).

Other insiders filing for Outlook Therapeutics, Inc. (OTLK)

Lundquist Kevin Michael, Chief Financial Officer
Jahr Robert Charles, Chief Executive Officer
Sukhtian Ghiath M., Director
KENYON LAWRENCE A, Chief Financial Officer
Sukhtian Faisal Ghiath, Director
Haddadin Yezan Munther, Director

How to read Form 4 transaction codes